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Abstract 
Calcium signaling is a critical regulator of cell proliferation. Elevated expression of calcium channels and 
pumps is a characteristic of some cancers, including breast cancer. We show that the plasma membrane 
calcium channel TRPV6, which is highly selective for Ca2+, is overexpressed in some breast cancer cell 
lines. Silencing of TRPV6 expression in a breast cancer cell line with increased endogenous TRPV6 
expression lead to a reduction in basal calcium influx and cellular proliferation associated with a 
reduction in DNA synthesis. TRPV6 gene amplification was identified as one mechanism of TRPV6 
overexpression in a sub-set of breast cancer cell lines and breast tumor samples. Analysis of two 
independent microarray expression datasets from breast tumor samples showed that increased TRPV6 
expression is a feature of estrogen receptor negative breast tumors encompassing the basal-like 
molecular subtype, as well as HER2-positive tumors. Breast cancer patients with high TRPV6 levels had 
decreased survival compared to patients with low or intermediate TRPV6 expression. Our findings 
suggest that inhibitors of TRPV6 may offer a novel therapeutic strategy for the treatment of estrogen 
receptor-negative breast cancers.  
 
  
3 
 
Introduction 
Calcium homeostasis is tightly controlled by various calcium-transporting proteins including calcium 
permeable ion channels (1). Increasing evidence suggests that some cancers may be associated with 
perturbed regulation of intracellular free Ca2+ via deregulation of the expression of specific calcium 
transporting-proteins (2, 3). Altered calcium signaling through such changes in expression may 
contribute to tumorigenesis via calcium-sensitive pathways such as apoptosis, migration, and 
proliferation (2-4). Examples of calcium channels contributing to altered calcium signaling in cancer cells 
include the store operated calcium channel ORAI1 and many members of the transient receptor 
potential (TRP) channel family (5-10).  
A TRP channel family member that has particularly high selectivity for Ca2+ and has constitutive activity is 
TRPV6 (11).  TRPV6 plays a critical role in calcium absorption by the intestine (12), with TRPV6 knockout 
mice exhibiting signs of calcium deficiency, such as decreased bone mineral density, defective intestinal 
calcium absorption and reduced fertility (13). Expression of TRPV6 mRNA and protein has been detected 
in placenta, pancreas, intestine, prostate and mammary gland (14-16). TRPV6 expression is elevated in 
prostate cancer compared to normal prostate and benign prostate hyperplasia and is associated with 
prostate cancer progression (17-19). Studies have also implicated TRPV6 as a regulator of proliferation; 
stable expression of TRPV6 in HEK-293 cells increases cell proliferation (20), whereas knockdown of 
TRPV6 in the LNCaP prostate cancer cell line decreases proliferation and induces apoptosis (21).  
Few studies have assessed TRPV6 in the context of breast cancer. Zhuang et al. (15) showed increased 
TRPV6 protein expression in two breast cancer tissue samples compared to normal breast. More 
recently and consistent with findings in prostate cancer (21), knockdown of TRPV6 decreases 
proliferation in T-47D breast cancer cells (7). This study also identified elevated mRNA levels (2 – 15 fold) 
of TRPV6 in 7 of 12 breast tumor samples (7).  A very recent study has demonstrated increased levels of 
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TRPV6 in more invasive breast cancers (22). However differences in TRPV6 have not been correlated 
with pathological (e.g. histological type) or molecular (e.g. estrogen receptor (ER) status or molecular 
subtypes) parameters or prognosis, as has recently been shown for regulators of store-operated calcium 
entry (9). In this study we assessed the consequences of TRPV6 siRNA-mediated down regulation on 
calcium homeostasis, the cell cycle and migration in breast cancer cells. We also explored TRPV6 gene 
copy number as a possible mechanism of regulating TRPV6 altered expression in breast cancer cell lines 
and in clinical breast cancer samples. Finally, we assessed whether TRPV6 expression is correlated with a 
specific subtype of breast cancer and to breast cancer survival. 
 
Materials and Methods 
Cell Culture 
The MDA-MB-231 and MCF-7 cell lines were obtained directly from ATCC. MDA-MB-468 (23), T47D, BT-
483, ZR-75-1, SKBR-3, 184A1 and 184B5 (24) cell lines were obtained as previously described. Upon 
receipt of each cell line, the cells expanded and primary, secondary, tertiary and working stocks were 
stored in liquid nitrogen. Cell lines were cultured for less than 10 passages (5-6 weeks) and separate 
media was used for each cell line. Cell lines were tested 6 monthly for mycoplasma contamination using 
the MycoAlert Mycoplasma Detection Assay (Lonza. Inc.; most recent test was September 2011) and 
monitored for morphological characteristics. Where appropriate, cell lines were characterized by 
assessment of the levels of HER2, ER, vimentin and E-cadherin using real time RT-PCR and/or 
immunohistochemistry as previously described (23). For studies that assessed the effect of TRPV6 down-
regulation in the T-47D breast cancer cell line the cells were maintained in Dulbecco’s Modified Eagle 
Medium, (high glucose) (DMEM; Invitrogen) supplemented with 10% FBS (FBS; Sigma Aldrich) and 4 mM 
L-Glutamine (Invitrogen) at 37°C with 5% CO2. 
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Real-time RT-PCR 
RNA for the analysis of TRPV6 in the cohort of cell lines and to confirm knockdown was isolated as 
previously described (24). RNA was reverse transcribed using the Omniscript RT kit (Qiagen) followed by 
real-time RT-PCR using TaqMan Universal PCR Master Mix and TaqMan gene expression assays. TRPV6 
was amplified using the TaqMan® Gene Expression Assay Hs00367960_m1. Thermal cycling was carried 
out using a StepOnePlus™ Real Time PCR System (Applied Biosystems) and universal cycling conditions. 
The mRNA levels were normalized to 18S rRNA and are presented relative to the appropriate control (as 
described in the figure legend). Relative expression levels were calculated using the comparative Ct 
method (25, 26). 
siRNA transfection 
ON-TARGETplus siRNA SMARTpool® siRNA reagents (consisting of four rationally designed siRNAs) were 
purchased from Dharmacon (Millennium Science, Australia). To reduce off-target effects these siRNAs 
have dual strand modification (27) and their design uses an algorithm to minimize seed region matches 
(28). General off-target effects of TRPV6 siRNA were assessed through assessment of changes in TRPV1, 
cyclophilin B and E-cadherin mRNA, no changes for these targets were detected in T-47D cells (data not 
shown). NT siRNA had no effect on cell viability compared to mock (Dharmafect 4 without siRNA) 
treated T-47D cells (data not shown). T-47D cells were seeded at 5 x 103 or 7.5 x 103 cells/well in 96-well 
plates and transfected with TRPV6 siRNA (100 nM, 25nM of each siRNA; L-003607-00-0005) or non-
targeting siRNA (NT siRNA; 100 nM, 25nM of each siRNA; D-001810-10-05) using 0.1 µL/well 
DharmaFECT 4 according to the manufacturer’s instructions. Knockdown of TRPV6 mRNA was assessed 
by real-time RT-PCR 24 h post transfection.  
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Measurement of Intracellular-free Ca2+ [Ca2+]I 
T-47D cells were seeded at 7.5 x 103 cells/well in a 96-well CellBIND® plates (Corning®) and transfected 
with the appropriate siRNA as described above. After 72 h [Ca2+]I was measured using the BD™ PBX 
Calcium Assay Kit (BD Biosciences)(29) as previously described with minor modifications (9). Briefly, cells 
were loaded with the Calcium Indicator and 500 µM probenecid in physical salt solution [PSS; 140 mM 
NaCl, 11.5 mM glucose, 10 mM HEPES, 5.9 mM KaCl, 1.4 mM MgCl2, 1.2 mM NaH2PO4, 5 mM NaHCO3, 
1.8 mM CaCl2, pH 7.3] for 1 h at 37°C. Cells were incubated for 15 min at room temperature. Loading 
solution was replaced with PBX signal enhancer and 500 µM probenecid in PSS with nominal Ca2+. 
BAPTA (500 µM) and CaCl2 (0.6 mM or 2 mM) were added to the cells sequentially and fluorescence was 
measured at 470-495 nm excitation and 515-575 nm emission using the fluorescence imaging plate 
reader FLIPRTETRA® (Molecular Devices). Response over baseline was assessed as a relative measure of 
[Ca2+]I (9) and rate of Ca
2+ influx was measured between 51 s and 151 s after Ca2+ addition as an 
assessment of TRPV6-mediated Ca2+ influx (7, 21). 
Cell number, Cell cycle and EdU incorporation 
Cell number, percentage of cells in S-phase, and cell cycle distribution were assessed in T-47D cells 120 h 
after siRNA treatment. T-47D cells were plated at 5 x 103 cells/well in 96-well BD Falcon™ microplates 
(BD Biosciences) and transfected with the appropriate siRNA. After 24 h, transfection medium was 
replaced with serum-free DMEM for 48-72 h. Cells were then incubated with DMEM supplemented with 
8% serum for 24 h or 48 h. Cells were treated with EdU (10 mmol/L) for 1 h and then fixed with 3.7% 
(v/v) formaldehyde in PBS, washed with 3% (w/v) BSA in PBS and permeabilized with 0.5% Triton X-100 
(v/v). Cells were then incubated with the Click-iT reaction cocktail (Alexa Fluor 555; Invitrogen), followed 
by DAPI (400 nM). Plates were scanned with the ImageXpress® Micro (Molecular Devices) automated 
epifluorescent microscope. Images were acquired with 10X objective, DAPI and EdU positive cells were 
7 
 
detected using DAPI-5060B and Cy3-4040B filter sets, respectively. For cell number and cell cycle 
analysis the DAPI integrated intensity was assessed using the cell cycle application module 
(MetaXpress®). The percentage of EdU positive cells was calculated using the multi wavelength cell 
scoring application module (MetaXpress®). 
Migration assay 
Cell migration assays were performed using BD FluoroBlok™ 8 µm cell culture inserts for 24-well plates 
(BD Biosciences). T-47D cells were seeded at 7.5 x 103 cells/well in a 96-well and transfected with the 
appropriate siRNA. After 72 h, the cells were trypsinized and seeded into the insert in serum-free DMEM 
(5 x 104cells/350 µL). DMEM media supplemented with 1% FBS was used as the chemoattractant. After 
24 h cells were labeled with 4 μg/mL Calcein AM (Invitrogen) for 1 h and fluorescence was detected at 
485 nm excitation and 520 nm emission using the NOVOstar fluorescent plate reader (BMG Labtech). 
Gene copy number assay 
TRPV6 gene copy number was assessed using a real-time TaqMan® Copy Number Assay (Applied 
Biosystems). Briefly, genomic DNA (gDNA) was isolated from breast cancer cell lines using the QIAamp 
DNA mini kit (Qiagen) and the DNA concentration was quantified using UV absorbance (A260/A280). A 20 
µL PCR reaction was prepared according to the Applied Biosystems TaqMan® Copy Number Assays 
instructions using 10 ng gDNA, TaqMan® Copy Number Reference Assay RNase P and a custom TaqMan® 
Assay (TRPV6_cn_for, GCTTCACCATGTGCTGCATCT; TRPV6_cn_rev, GGCTCGTGCGGTTATTGG; 
TRPV6_cn_pr_FAM, 6-FAM-CCCCTCAAGCCCAGG). All assays were performed in quadruplicate using the 
StepOnePlus™ Real Time PCR System (Applied Biosystems). Data were analyzed using CopyCaller™ v1.0 
software (Applied Biosystems) by performing a comparative (ΔΔCt) relative quantitation analysis. The 
ΔCt was determined by calculating the difference between the Ct values for TRPV6 and the reference 
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assay, RNase P. The ΔΔCt was then measured by comparing the ΔCt for TRPV6 and the control gDNA 
(Applied Biosystems) which was assigned diploid copy number.  
Analysis of publically available microarray data 
The TRPV6 gene resides at chromosome 7: 142,279,082-142,293,599 (hg18 assembly). Two cohorts of 
samples with whole genome DNA copy number data from different microarray platforms were analyzed 
to determine whether somatic alterations in DNA copy number occur in the TRPV6 gene region in breast 
tumors. The first cohort consisted of 35 invasive ductal carcinomas, of which 22 were ER-positive and 13 
were ER-negative, analyzed by 4.7k BAC-microarray comparative genomic hybridization (aCGH) (30). The 
second cohort was derived from The Cancer Genome Atlas (TCGA) and consisted of 247 samples 
analyzed using the Affymetrix Genome-Wide Human SNP Array 6.0. SNP6.0 CEL files for each sample 
consisting of level 3 pre-processed data of segmental values were downloaded from the TCGA Data 
Portal (31). The data was processed in R version 2.13.0 to score DNA copy number alterations, as 
described by others (32). Briefly the thresholds of <-0.3 and >0.3 were assigned to call losses and gains, 
respectively, and the amplitude of gain at the region of the TRPV6 gene was assessed specifically by 
using thresholds of >0.3, >0.6, >0.8 and >1.0. To determine the status of TRPV6 gene copy number in 
different subtypes of breast cancer, this cohort was stratified using clinicopathological data available 
from the TCGA according to histological type (invasive ductal carcinoma (IDC) or invasive lobular 
carcinoma (ILC)) and biomarker expression status (ER, progesterone receptor (PR), HER2) into the 
following groups: ILC, IDC ER+/HER2-, IDC ER+/HER2+, IDC ER-/HER2+, IDC ER-/PR-/HER2-. This cohort 
was also stratified according to molecular subtype based on the gene expression profiling data from the 
same samples and using the Single Sample Predictor defined by Hu et al. (33). 
To assess the gene expression patterns of TRPV6 in breast cancer, data were downloaded for the 
following two studies, the TCGA (see above) and the NKI-295 dataset (34). For the TCGA data, level 2 
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(log2 lowess normalized) gene expression data for 371 tumors was downloaded from the data portal. In 
the NKI-295 dataset, the TRPV6 gene was annotated under a previous name, ABP/ZF.  The samples were 
stratified, as described above, using clinicopathological data according to ER status, molecular subtype 
and histological type plus ER/PR/HER2 biomarker expression (TCGA data only). 
Statistical analysis 
Statistical significance was assessed as described in individual figure legends. Data analysis was 
performed using Prism version 5.02 for Windows (GraphPad Inc). 
 
Results 
TRPV6 is overexpressed in a subset of breast cancer cell lines 
Increased TRPV6 levels are a feature of T-47D breast cancer cells compared to MDA-MB-231 and MCF-7 
breast cancer cells (35). TRPV6 expression is also elevated (2-15 fold) in 7 of 12 clinical breast tumors (7). 
To begin to assess if TRPV6 overexpression may be a feature of specific breast cancer subtypes we 
assessed TRPV6 levels in a bank of non-malignant and malignant breast cancer cell lines varying in ER, PR 
and HER2 status and molecular subtype. TRPV6 levels were elevated in 4 cell lines; ZR-75-1, T-47D, SK-
BR-3 and MDA-MB-468 compared to the non-malignant breast cancer cell lines 184A1 and 184B5 (Fig. 
1A). Levels in these four breast cancer cell lines were greater than 60 fold higher relative to 184A1 cells 
(Fig. 1A), whereas TRPV6 levels in MDA-MB-231, MCF-7 and BT-483 were similar (< 7 fold higher to 
those observed in 184A1 cells) (Fig. 1A). 
Knockdown of TRPV6 reduces the rate of calcium influx 
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TRPV6 basal Ca2+ influx has previously been assessed as a measure of TRPV6 function in HEK293 cells 
transiently overexpressing TRPV6 (36), in LNCaP prostate cancer cells (21) and in T-47D breast cancer 
cells, where a functional consequence of TRPV6 siRNA was shown by the addition of supra-physiological 
levels of extracellular Ca2+ (10 mM) (7). Here we investigated the effect of TRPV6 knockdown via siRNA 
(Fig. 1B) on the function of the TRPV6 channel basal calcium influx in T-47D breast cancer cells. We 
observed a basal Ca2+ influx reduced by 44% after the addition of either 0.6 mM or 2 mM extracellular 
calcium in cells with TRPV6 targeted knockdown compared to cells with non-targeting control (Fig. 1C 
and 1D). These results demonstrate functional alterations in calcium homeostasis associated with TRPV6 
knockdown in T-47D breast cancer cells at physiological concentrations of extracellular Ca2+ re-addition.  
Effect of TRPV6 knockdown on viable cell number, cell cycle, and migration 
We investigated potential effect of TRPV6 down-regulation (Fig. 2A) on the cell cycle and cell migration 
in T-47D breast cancer cells. TRPV6 siRNA significantly reduced the number of viable cells at 24 h and 48 
h (35% and 40% reduction, respectively) in the presence of serum (Fig. 2B). Assessment of proliferating 
cells using EdU staining, showed that the percentage of cells in S-phase significantly decreased (∼20%) 
with TRPV6 knockdown (Fig. 2C). DNA-content histogram analysis showed that TRPV6 knockdown 
caused cells to accumulate in the G1-phase at 24 h with serum (Fig. 2D), but not at 48 h with serum (Fig. 
2E). Knockdown of TRPV6 did not decrease T-47D migration; instead a modest increase was observed 
(Fig. 2F). 
TRPV6 gene amplification in a bank of breast cancer cell lines 
To assess whether gene amplification could be a mechanism for TRPV6 mRNA overexpression in some 
breast cancer cell lines, gene copy number was assessed using a real-time assay. TRPV6 copy number 
was greater than 6 in T-47D, SK-BR-3, ZR-75-1, BT-483 and MCF-7 cells (Fig. 3A). The highest level was 
detected in BT-483 cells (9 copies) (Fig. 3A). Overexpression of TRPV6 mRNA in ZR-75-1, T-47D and SK-
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BR-3 cells may be due, at least in part, to increased gene copy number (Fig. 3B). However, an association 
between gene copy number and mRNA levels for TRPV6 was not observed for MDA-MB-231, MCF-7, BT-
483 or MDA-MB-468 cells (Fig. 3B). 
TRPV6 gene amplification in clinical breast tumors 
To ascertain if TRPV6 gene is subjected to copy number alteration in human breast tumor samples, 
TRPV6 gene copy number was examined in data from two cohorts of invasive carcinomas derived from 
BAC aCGH (cohort 1) (30) and SNP-CGH (TCGA – cohort 2) platforms. The genomic region harboring the 
TRPV6 gene was subjected to both gains and deletions. The frequency of these gains and deletions 
differed across different tumor subtypes (Table 1). For instance, both cohorts demonstrated a significant 
increase in the frequency of TRPV6 gene copy number gains in ER-negative tumors relative to ER-
positive tumors (P < 0.01). This finding was also observed when triple negative tumors (ER-, PR-, and 
HER2-negative) were compared to ER-positive or HER2-positive tumors and when basal-like tumors 
were compared to luminal A or HER2 tumor types (P < 0.01; Table 1). 
The amplitude of gain was further measured using different thresholds for calling gains to determine the 
number of tumors with higher level gains (amplifications) in the region of TRPV6 (Fig. 4A and 4B) and 
determine, according to the copy number profile, whether there was a specific amplification in this 
region or whether the region was gained as part of an increase copy number covering a large region of 
the chromosome. Figure 4A shows a peak in gains very close to, but not encompassing the TRPV6 gene 
locus, highlighted by the red line. We identified 6 tumors overall (4 from cohort 1 and 2 from cohort 2) 
that had specific amplification in the region of the TRPV6 gene (Fig. 4A and 4B), the increase in copy 
number for the remaining samples were reflected by increased DNA copy number of chromosome 7q 
not specifically related to TRPV6 gene region. The gene region was lost most frequently in HER2 tumors 
when compared to ER-positive or triple negative tumors and in comparison to basal-like tumors (P < 
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0.01; Table 1). The correlation between TRPV6 gene copy number and TRPV6 mRNA levels was strongest 
for the basal-like subtype compared to other molecular subtypes (Fig. 4C). 
TRPV6 gene expression in clinical breast tumors and association with survival 
Given the evidence from the current study and others, that TRPV6 overexpression is a feature of some 
specific breast cancers, we evaluated published transcription profiling data from two independent 
cohorts of invasive breast tumors, the NKI-295 dataset comprising 295 primary tumors (34) and TCGA 
comprising 372 tumors. The gene expression levels were assessed in tumors stratified according to ER 
status, molecular subtype and immunophenotype. These results showed that TRPV6 mRNA levels are 
increased in ER-negative tumors compared to ER-positive tumors (Fig. 5A and 5B). When the tumors in 
the cohort were assigned to molecular subtypes based on the gene expression profiles, TRPV6 
expression was significantly elevated in basal-like and HER2 breast tumors compared to luminal A and 
luminal B breast tumors (Fig. 5C and 5D). Additionally, when stratified by immunophenotype, TRPV6 
expression was elevated in HER2-positive and triple negative ductal tumors compared to ER-positive, 
HER2-negative tumors (Fig. 5E). Finally, when the tumors were stratified according the level of TRPV6 
mRNA expression, tumors with the highest levels of expression (upper quartile) were associated with a 
significantly reduced overall survival when compared to tumors in the intermediate or lower quartiles 
(Fig. 5F). 
Discussion 
TRPV6 is an essential calcium influx channel, which has been implicated in prostate cancer progression 
(18, 19). Elevated TRPV6 expression is seen in breast tumors (7), however, the mechanism of 
overexpression has not been addressed and a correlation with tumor subtype or prognosis also not 
determined. Our studies identify TRPV6 gene amplification as a possible mechanism for TRPV6 
overexpression in some breast tumors. We provide further evidence for a role for TRPV6 in tumor 
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progression with siRNA-mediated inhibition of TPRV6 reducing basal Ca2+ influx and breast cancer cell 
proliferation. Increased TRPV6 expression was a feature of ER-negative, HER2 and basal-like breast 
tumors and increased TRPV6 levels were associated with reduced survival in breast cancer patients. 
Elevated TRPV6 mRNA levels have previously been observed in seven of 12 clinical breast cancer 
samples and in the T-47D breast cancer cell line compared to the MDA-MB-231 and MCF-7 cell lines (7). 
Elevated TRPV6 was identified in four of seven breast cancer cell lines assessed in this study with no 
obvious correlation between TRPV6 expression levels and molecular subtype but this may simply be due 
to the small number of cell lines examined. Analysis of two independent cohorts of clinical samples, 
however, identified a correlation between TRPV6 mRNA expression levels and i) immunophenotype and 
ii) molecular subtypes. These data highlight a potential biological role for TRPV6 in specific breast cancer 
subtypes. For instance the highest TRPV6 mRNA levels were consistently associated with invasive ductal 
carcinomas with an ER-negative phenotype, whether they were classified simply as ER-negative, as triple 
negative (ER-, PR- and HER2-negative) or as basal-like (gene expression profiling subtype). The 
correlation we observed between elevated TRPV6 expression and a significantly decreased survival may 
reflect the association between TRPV6 expression and the ER-negative subgroup, which are among 
those breast cancers with the worst prognosis (37, 38). 
Genome-wide, high resolution studies of breast cancer samples show that between 10.5 - 12% of 
overexpressed genes are associated with gene amplification (39, 40). We explored whether increased 
gene copy number was a potential driver of enhanced expression levels seen in some breast cancers. 
We found an association between increased TRPV6 mRNA expression and increased TRPV6 gene copy 
number in three breast cancer cell lines, ZR-75-1, T-47D and SK-BR-3. Analysis of clinical breast cancer 
samples showed that although TRPV6 gene does not reside within a region of the genome that is 
frequently amplified in breast cancer (such as, 8p12, 8q24, 11q13, 17q12 (41)), the gene was subjected 
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to frequent somatic alteration and that elevated copy number was most likely to occur in ER-negative, 
triple negative or basal-like compared to other subtypes.  
We tested whether there was a correlation between TRPV6 gene expression levels and gene copy 
number data in the TCGA cohort of clinical samples, where both data were available. The highest 
correlation was found in the basal-like subgroup where a proportion of tumors exhibited both an 
elevated DNA copy number and an increased mRNA level. The data suggest gene amplification as a 
possible mechanism for driving TRPV6 overexpression in these cell lines and tumors. In contrast, TRPV6 
expression did not correlate with gene copy number in four breast cancer cell lines and in many tumors, 
suggesting that there is an alternative mechanism driving the high levels of gene transcription. This 
scenario is not unexpected in breast cancer, since mRNA levels are not always linearly related to gene 
copy number and where numerous alternative mechanisms for regulating transcription exist, including 
altered miRNA regulation, DNA methylation or transcriptional activation (42). Solvnang et al. (42) 
showed that a quadratic relationship for copy number and mRNA expression was a better fit than a 
linear relationship for more than 80% of the breast tumors assessed.  Furthermore a gene may exhibit 
two expression sub-sets in a breast cancer cohort; such as amplification without a corresponding 
increase in expression and increased expression without amplification (42). Such a scenario may exist for 
TRPV6 in breast cancer cell lines and tumors. 
The functional role for TRPV6 was investigated in the T-47D breast cancer cell line, which has elevated 
TRPV6 mRNA expression and gene copy number. Knockdown of TRPV6 using siRNA significantly 
decreased basal Ca2+ influx with the addition of physiological levels of Ca2+, consistent with the one 
previous study of TRPV6 activity in a breast cancer cell line (7). Our current findings and those of Bolanz 
et al. (7) also identify a reduction in viable cell number with TRPV6 siRNA treatment in T-47D cells. While 
Bolanz et al. (7) suggested an increase in the number of cells undergoing apoptosis our data also suggest 
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that TRPV6 siRNA reduces the percentage of cells in S-phase and increases the percentage of cells in the 
G1-phase. Ca2+ influx is a well known mechanism to promote the G1 to S-phase transition (43), therefore 
the accumulation of cells in G1-phase is likely to be associated with the attenuation of calcium influx 
associated with TRPV6 inhibition. LNCaP prostate cancer cells also have a reduction in cells in S-phase, 
but no affect on the percentage of cells in the G1-phase with TRPV6 knockdown (21). This indicates 
some potential divergent roles for TRPV6 on cell cycle in breast and prostate cancer cells. Although, 
TRPV6 down-regulation decreases breast cancer cell proliferation, knockdown of TRPV6 expression 
actually increased T-47D breast cancer cell migration, even though viable cell number was reduced. This 
may suggest that the influence TRPV6 has on outcome or prognosis is via mechanisms other than tumor 
cell migration. However, this is in contrast to a very recent study in MDA-MB-231 and MCF-7 breast 
cancer cell lines, where TRPV6 silencing reduced migration (22). Further studies assessing the role of 
TRPV6 in the migration of other breast cancer cell lines are now required. 
The potential requirement for TRPV6 function specifically in tumor cell proliferation, through calcium 
influx, may highlight the underlying association between elevated TRPV6, an ER-negative tumor 
phenotype and poor outcome, since ER-negative tumors are most often of high grade and are highly 
proliferative tumors. It is unclear from this study whether TRPV6 overexpression drives or simply 
facilitates this enhanced proliferation in this aggressive breast tumor subtype. Nevertheless, targeted 
knockdown of the gene in cells with elevated expression leads to reduced growth and stalling of the cell 
cycle suggesting that targeting the TRPV6 calcium channel maybe a useful therapeutic mechanism.  
There is a requirement for targeted therapeutics in ER-negative, non-HER2 positive tumors owing to the 
lack of clinical benefit derived from giving these patients current targeted therapy (44) (Herceptin® or 
endocrine-based treatment). Chemotherapeutics such as taxanes do provide clinical benefit and the use 
of poly(ADP-ribose) polymerase inhibitors (PARPi) show promise by targeting apparent defects in DNA 
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repair mechanisms in this category of breast tumors (45, 46). Much still needs to be resolved regarding 
the role of PARPi in treating ER-negative tumors and recent phase III clinical data for PARPi are 
somewhat disappointing (47) indicating that alternative therapeutic options, such as targeting calcium 
signaling are warranted.  
Inhibition of the calcium channel TRPV6 may not be associated with the predicted systemic side effects 
that would result from inhibition of some other calcium channels, since TRPV6 knockout mice are viable 
and exhibit traits that may be well tolerated compared to current therapies (e.g. decreased bone 
mineral density and defective intestinal calcium absorption (13)). Our studies indicate that TRPV6 
inhibitors are potential therapeutics for the treatment of ER-negative breast cancers that exhibit 
elevated TRPV6 expression. 
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Table 1: DNA copy number status of TRPV6 gene region in breast cancer subtypes  
Cohort 1 Total Gains No Gains p-value Losses No Losses p-value 
IDC 35 12 (34%) 23 (66%)  6 (17%) 29 (83%)  
IDC ER+ 22 3 (14%) 19 (86%)  5 (23%) 17 (77%)  
IDC ER- 13 9 (69%) 4 (31%) 0.00221  1 (8%) 12 (92%)  
Cohort 2 Total Gains No Gains p-value Losses No Losses p-value 
IDC 206 23 (11.2%) 183 (88.8%)  24 (11.6%) 182 (88.4%)  
ILC 23 2 (8.7%) 21 (91.3%)  4 (17.4%) 19 (82.6%)  
IDC ER+ 167 12 (7.2%) 155 (92.8%)  22 (13.2%) 145 (86.8%)  
IDC ER- 39 11 (28.2%) 28 (71.8%) 0.00072 2 (5.1%) 37 (94.9%)  
IDC (ER+/HER2-) 145 11 (9.1%) 134 (90.0%) 0.00023 14 (9.7%) 131 (90.3%) 0.00605 
IDC (HER2+) 30 1 (4.5%) 29 (95.5%) 0.00264 9 (30%) 21 (70%)  
IDC (ER-/PR-/HER2-) 31 11 (35.4%) 20 (64.6%)  1 (3.2%) 30 (96.8%) 0.00576 
Molecular Subtype 247 25 (10.1%) 222 (89.9%)  31 (13.0%) 215 (87.0%)  
Luminal A 93 5 (5.4%) 88 (94.6%) 0.00317 11 (11.8%) 82 (88.2%)  
Luminal B 60 6 (10%) 54 (90%)  10 (16.7%) 50 (83.3%) 0.03199  
HER2 40 2 (5%) 38 (95%) 0.02198 9 (22.5%) 31 (77.5%)  
Basal-like 54 12 (22.2%) 42 (77.8%)  2 (3.7%) 52 (96.3%) 0.007810 
+: positive; -: negative; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; ER: estrogen receptor; PR: progesterone receptor. 
Statistical analysis was performed using Fisher’s exact test, two tailed, and only significant (< 0.05) P-values are displayed.   
1: cohort 1 IDC ER+ vs. ER-; 2:  cohort 2 IDC ER+ vs. ER-; 3: IDC (ER-/PR-/HER-) vs. IDC (ER+/HER2-); 4: IDC (ER-/PR-/HER-) vs. IDC (HER2+); 5: IDC 
(HER2+) vs. IDC (ER+/HER2-); 6: IDC (HER2+) vs. IDC (ER-/PR-/HER-); 7: Basal-like vs. luminal A; 8: Basal-like vs. HER2; 9: luminal B vs. Basal-like; 
10: HER2 vs. Basal-like. 
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Figure legends 
Figure 1: Characterization of TRPV6 in breast cell lines. A, TRPV6 mRNA levels in non-malignant 184A1 
and 184B5 and malignant MDA-MB-231, MCF-7, BT-483, ZR-75-1, T-47D, SK-BR-3 and MDA-MB-468 
breast cell lines. Molecular features of these lines (according to (48, 49)) is given: ER, estrogen receptor; 
PR, progesterone receptor; Bb, Basal B; Ba, Basal A; L, Luminal. Data represent the mean ±SD (N = 3) and 
are representative of two independent assays. B, Relative TRPV6 mRNA levels in T-47D breast cancer 
cells 24 h after treatment with non-targeting siRNA (NT siRNA) or TRPV6 siRNA. The data are mean ±SD 
(N = 4) and are from two independent experiments and * P < 0.001 compared with NT siRNA using an 
unpaired t-test. C and D, effect of TRPV6 down-regulation on basal Ca2+ influx. C, relative [Ca2+]i as mean 
fluorescence relative to baseline (N = 3). Cells were treated with 2 mM (solid line) or 0.6 mM Ca2+ 
(dotted line). Data are representative of three independent assays carried out in triplicate. D, rate of 
Ca2+ influx between 51s and 151s after Ca2+ addition. Data are from three independent assays carried 
out in triplicate (mean ±SD; N = 9) and * P < 0.001 compared with NT siRNA using an unpaired t-test. 
 
Figure 2: Effect of TRPV6 down-regulation in the T-47D breast cancer cell line. TRPV6 was knocked down 
in T-47D cells using siRNA, and the effect on viable cell number, cell cycle, and migration was assessed 
compared with non-targeting siRNA (NT-siRNA). A, Relative TRPV6 mRNA levels in T-47D breast cancer 
cells 120 h after treatment with non-targeting siRNA (NT siRNA) or TRPV6 siRNA. The data are mean ±SD 
(N =3) and are from three independent experiments.* P < 0.05 compared with NT siRNA using an 
unpaired t-test. B-F, Data are mean ±SD (N = 9) from 3 independent experiments. *P  <  0.05 compared 
with NT siRNA using an unpaired t-test. B, effect of TRPV6 knockdown on total cell number. C, effect of 
TRPV6 knockdown on the percentage of EdU positive cells. D and E, effect of TRPV6 down regulation on 
the cell cycle in T-47D cells that were treated with serum for 24 h (D) or 48 h (E) after serum deprivation. 
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The left panel depicts a representative frequency distribution of nuclear DAPI integrated intensity of 
three independent experiments. The right panel depicts the percentages of cells in G1, S and G2/M 
phase as mean ± SD from three independent experiments performed in triplicate. *P < 0.05 compared 
with NT siRNA using an unpaired t-test. F, effect of TRPV6 siRNA on migration expressed as fluorescence 
relative to NT siRNA. *P < 0.05 compared with NT siRNA using an unpaired t-test. 
Figure 3: Characterization of TRPV6 copy number in breast cell lines. A, TRPV6 gene copy number in 
control genomic DNA (gDNA) and malignant MDA-MB-231, MCF-7, BT-483, ZR-75-1, T-47D, SK-BR-3 and 
MDA-MB-468 breast cancer cell lines. The data are mean ±SD (N = 8) and are from two independent 
experiments carried out in quadruplicate. B, comparison of mRNA expression relative to 184A1 and gene 
copy number in breast cancer cell lines. 
Figure 4: TRPV6 gene copy number in breast tumors. A, chromosome 7 frequency plots of SNP-CGH data 
derived from samples of invasive breast tumors (from The Cancer Genome Atlas) classified as either 
HER2 or basal-like molecular subtype. X-axis: chromosome location (in base pairs); y-axis: proportion of 
cohort with gain along this chromosome. TRPV6 gene region is highlighted by a red line. B, a profile of 
chromosome 7 copy number (from BAC aCGH) from an invasive ductal carcinoma. X-axis: chromosome 
location; y-axis: normalized, scaled log2 ratios of individual BAC clones. The arrow indicates a specific 
amplification of the region harboring the TRPV6 gene. C, correlation between TRPV6 gene copy number 
and mRNA levels in the TCGA cohort of human breast tumors. Data were stratified according to 
molecular subtype.  X-axis: DNA copy number at TRPV6 gene region according to segmental DNA values 
(level 3 data); y-axis: log2 lowess normalized values for TRPV6 mRNA expression levels. A Pearson’s 
correlation coefficient (R-values) was calculated to measure the relationship between gene copy 
number and its mRNA expression profile.   
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Figure 5: TRPV6 in breast cancer samples from two independent cohorts. Relative TRPV6 expression 
levels were assessed in the TCGA (A, C and E) and NKI-295 (B, D and F) microarray datasets. Horizontal 
lines represent median values and *P  <  0.05 using Kruskal-Wallis test with Dunn’s post-test for multiple 
comparisons. A and B, breast tumors were allocated to estrogen receptor (ER)-negative or ER-positive 
and * indicates significance compared to ER-positive. C and D, breast tumors were allocated to 
molecular subtypes and * and ^ indicates significance compared Luminal A and Luminal B, respectively. 
E, breast tumors were allocated to histopathological subtypes and immunophenotypes * indicates 
significance compared to ER-positive, HER2-negative; Duc, ductal; Lob, Lobular; Other, tumors of other 
histological type or with incomplete pathological/clinical data, e.g. no type or ER data. F, TRPV6 
expression in the upper quartile is associated with reduced survival in breast cancer patients. Kaplan-
Meier analysis, patient survival was compared between tumors in the upper, intermediate and lower 
quartile of TRPV6 expression. Significance was tested using the log-rank test. 
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